Compounds Discovered In Asia Expected To Enter Clinic In Three Years, Pfizer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Outstanding talent and patient needs for Asians are the main reason to be in Asia, not cost, Pfizer R&D exec Mackay stressed at a Singapore press conference.